Janssen Reports Post-Hoc Analysis of P-III GRIPHON and P-IIIb TRITON Studies of Uptravi (selexipag) for the Treatment of Pulmonary Arterial Hypertension #ESC2021

Pharma

 Janssen Reports Post-Hoc Analysis of P-III GRIPHON and P-IIIb TRITON Studies of Uptravi (selexipag) for the Treatment of Pulmonary Arterial Hypertension #ESC2021

Janssen Reports Post-Hoc Analysis of P-III GRIPHON and P-IIIb TRITON Studies of Uptravi (selexipag) for the Treatment of Pulmonary Arterial Hypertension #ESC2021

Shots:

  • The P-III GRIPHON & P-IIIb TRITON trials evaluate Uptravi vs control group in 404 & 245 patients with PAH, respectively
  • The results from a post-hoc pooled analysis showed a 52% reduction in the risk of disease progression @6mos., Additionally, 48% reduction in the risk of disease progression among patients who received triple therapy group, AEs were consistent with the known safety profiles of Uptravi
  • Uptravi (PO) is a selective, prostacyclin IP receptor agonist approved in the EU for PAH in adult patients with WHO FC II-III, either as combination therapy in patients insufficiently controlled with ERA & PDE5i, or as monothx. in patients who are temporarily unable to take oral therapies

Click here to­ read full press release/ article | Ref: Businesswire | Image: Clincal Trials Arena


Post Views:
46

Leave a Reply